Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas

1 Jan 2008

Abstract excerpt

BCL6 is a transcriptional repressor often expressed constitutively in diffuse large B-cell lymphomas (DLBCL) due to mutations of its genomic locus. BCL6 mediates aberrant survival, proliferation, genomic instability and differentiation blockade in DLBCL cells. The biochemical study of BCL6 mediated gene repression has provided the basis for design of agents that inhibit BCL6 and kill lymphoma cells. The repressor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Lymphoma Diagnosis and Treatment
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18452090
DOI: 10.1080/10428190801895345

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomasPMID 18452090Read ↗

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and BeyondSemantic proximity Read ↗

BCL6 as a therapeutic target for lymphoma.Semantic proximity Read ↗

Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6Semantic proximity Read ↗

BCL6 represses NFκB activity in diffuse large B‐cell lymphomasSemantic proximity Read ↗

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphomaSemantic proximity Read ↗

Novel Small Molecule DZ-865B Effectively Degrades BCL6, Promotes Apoptosis and Reduces Proliferation of Diffuse Large B-Cell Lymphoma CellsSemantic proximity Read ↗

Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomasSemantic proximity Read ↗

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphomaSemantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivoSemantic proximity Read ↗

B Cell Lymphoma 6 (BCL6): A Conserved Regulator of Immunity and BeyondSemantic proximity Read ↗

Mechanisms of action of BCL6 during germinal center B cell developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.